2. Academic Validation
  3. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

  • Biochem Biophys Res Commun. 2021 Nov 12;578:91-96. doi: 10.1016/j.bbrc.2021.09.023.
Dong-Kyun Ryu 1,  Bobin Kang 1,  Hanmi Noh 1,  Sun-Je Woo 2,  Min-Ho Lee 3,  Patricia M Nuijten 4,  Jong-In Kim 1,  Ji-Min Seo 1,  Cheolmin Kim 1,  Minsoo Kim 1,  Eunji Yang 2,  Gippeum Lim 2,  Seong-Gyu Kim 2,  Su-Kyeong Eo 2,  Jung-Ah Choi 2,  Manki Song 2,  Sang-Seok Oh 3,  Hyo-Young Chung 3,  Aloys Sl Tijsma 4,  Carel A van Baalen 4,  Ki-Sung Kwon 1,  Soo-Young Lee 5
Affiliations

Affiliations

  • 1 Biotechnology Research Institute, Celltrion Inc., Incheon, South Korea.
  • 2 Science Unit, International Vaccine Institute, Seoul, South Korea.
  • 3 New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, South Korea.
  • 4 Viroclinics Biosciences, Rotterdam, the Netherlands.
  • 5 Biotechnology Research Institute, Celltrion Inc., Incheon, South Korea. Electronic address: sooyoung.lee@celltrion.com.
PMID: 34547629 DOI: 10.1016/j.bbrc.2021.09.023
Abstract

The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the Antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants Infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants.

Keywords

CT-P59; Delta; Gamma; Regdanvimab; SARS-CoV-2 variant; Therapeutic antibody.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z